David Miller
Private Equity Investor at Alpine Bioventures, GP, LLC
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mitchell Gold | M | 57 |
Alpine Bioventures, GP, LLC
 Alpine Bioventures, GP, LLC Investment ManagersFinance Alpine Bioventures, GP, LLC (Alpine Bioventures) is a venture capital firm founded by Mitchell H. Gold in 2013. The firm is headquartered in Seattle, Washington. | 7 years |
| Jay Venkatesan | M | 52 |
Alpine Bioventures, GP, LLC
Alpine Bioventures, GP, LLC Investment ManagersFinance Alpine Bioventures, GP, LLC (Alpine Bioventures) is a venture capital firm founded by Mitchell H. Gold in 2013. The firm is headquartered in Seattle, Washington. | 9 years |
| Remy Durand | M | 38 |
Alpine Bioventures, GP, LLC
Alpine Bioventures, GP, LLC Investment ManagersFinance Alpine Bioventures, GP, LLC (Alpine Bioventures) is a venture capital firm founded by Mitchell H. Gold in 2013. The firm is headquartered in Seattle, Washington. | 6 years |
| James Rickey | M | 45 | 7 years | |
| James Topper | M | 62 | 8 years | |
| Peter Thompson | M | 64 | 8 years | |
| Christopher Peetz | M | 45 | 6 years | |
| Xiang Ming Cui | M | 55 | 5 years | |
| Robert Conway | M | 70 | 7 years | |
| Stanford Peng | M | 53 | 7 years | |
| Jae Uk Jeong | M | - |
Curevo, Inc.
 Curevo, Inc. BiotechnologyHealth Technology Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone. | 2 years |
| Charles Petty | M | - |
Curevo, Inc.
Curevo, Inc. BiotechnologyHealth Technology Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone. | 2 years |
| Baeksik Bae | M | - |
Curevo, Inc.
Curevo, Inc. BiotechnologyHealth Technology Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone. | 2 years |
| Steven Reed | M | 73 |
Curevo, Inc.
Curevo, Inc. BiotechnologyHealth Technology Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone. | - |
| Mario Barro | M | - |
Curevo, Inc.
Curevo, Inc. BiotechnologyHealth Technology Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone. | 2 years |
| George Simeone | M | - |
Curevo, Inc.
Curevo, Inc. BiotechnologyHealth Technology Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone. | - |
| Charlie Petty | M | - |
Curevo, Inc.
Curevo, Inc. BiotechnologyHealth Technology Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone. | 3 years |
| Thaedra Thullberry | F | - | 7 years | |
| Lisa Shelton | F | - |
Curevo, Inc.
Curevo, Inc. BiotechnologyHealth Technology Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone. | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Paul Sekhri | M | 65 | 4 years | |
| Mark Litton | M | 56 | 1 years | |
| Jon Congleton | M | 60 | - | |
| R. Carruthers | M | 66 | - | |
| Ryan Swanson | M | - | 4 years | |
| Kent Lewis | M | - |
Western Washington University
| 4 years |
| Kristine Swiderek | M | - | 3 years | |
| Thomas Hilbert | M | - |
Western Washington University
| 3 years |
| Mark Owings | M | - |
Western Washington University
| 4 years |
| Gregory Johnson | M | 58 |
Western Washington University
| 4 years |
| Randall Cooley | M | - |
Western Washington University
| 4 years |
| Janice Troha | F | - | - | |
| Renae Bell | F | 57 |
Western Washington University
| 4 years |
| Daniel P. Jacoy | M | - |
Western Washington University
| 3 years |
| Danielle Bennett | F | - | 2 years | |
| Daniel Tolley | M | 55 |
Western Washington University
| 4 years |
| Robert Carter | M | - |
Western Washington University
| - |
| Neil Powell | M | - |
Western Washington University
| 3 years |
| David L. Fleming | M | - |
Western Washington University
| 4 years |
| Matt Beardsley | M | - |
Western Washington University
| 4 years |
| Scott Ronk | M | - |
Western Washington University
| 4 years |
| Eric Waggoner | M | - |
Western Washington University
| 4 years |
| Doug Milnor | M | - |
Western Washington University
| 4 years |
| Todd Rawls | M | - |
Western Washington University
| 4 years |
| Keith Williams | M | - |
Western Washington University
| 4 years |
| Sandra Anderson | F | - |
Western Washington University
| 4 years |
| Sean Gleason | M | - |
Western Washington University
| 4 years |
| Alfredo Garcia | M | 58 |
Western Washington University
| 1 years |
| Ralph Braun | M | 57 |
Western Washington University
| 2 years |
| Michael Scott Hamilton | M | - |
Western Washington University
| 2 years |
| Marc D. Durand | M | 58 |
Western Washington University
| 4 years |
| Kaylene M. Lahn | F | - |
Western Washington University
| 4 years |
| Allen Muhich | M | 57 |
Western Washington University
| 4 years |
| George P. Doyle | M | 54 |
Western Washington University
| 4 years |
| Catherine Udd | F | - |
Western Washington University
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 46 | 85.19% |
| India | 8 | 14.81% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- David Miller
- Personal Network
